摘要
目的探寻针对X连锁低磷血症(XLH)患者成纤维细胞生长因子23(FGF23)过度表达的靶向药物。方法归纳Burosumab的药理作用机制、用法用量、药物代谢动力学,以及该药的各期临床试验及不良反应发生情况。结果与结论Burosumab对XLH的疗效优于常规疗法,患儿(≥1岁)及成年患者均适用。该药靶向明确,生物利用度高,半衰期长,耐受性良好,可提高血清磷浓度,增加肾小球对磷的重吸收,改善骨矿化,并减轻佝偻病的严重程度及疼痛。不良反应均为轻度或中度,且多无需干预。
Objective To explore targeted drugs for the overexpression of fibroblast growth factor 23(FGF23)in patients with X-linked hypophosphatemia(XLH).Methods The pharmacological mechanism,dosage and pharmacokinetics of Burosumab,as well as the clinical trials of each phase and the incidence of adverse reactions of the drug were summarized.Results and Conclusion Burosumab is supe-rior to conventional therapy in the treatment of XLH,and it is suitable for both children(≥one year old)and adult patients.The drug has clear targeting,high bioavailability,long half-life and good tolerance.It can increase the concentration of serum phosphorus,in-crease the reabsorption of phosphorus by the glomerulus,improve bone mineralization,and reduce the severity and pain of rickets.The adverse reactions are mild or moderate,and most of them did not need to be intervention.
作者
屈扬扬
白秋江
QU Yangyang;BAI Qiujiang(Department of Pharmacy,Tangshan People's Hospital,Tangshan,Hebei,China 063001;Department of Pharmacy,Taikang Xianlin Drum Tower Hospital Affiliated to Medical School of Nanjing University,Nanjing,Jiangsu,China 210046)
出处
《中国药业》
CAS
2021年第23期124-128,共5页
China Pharmaceuticals
